Tessellate BIO

Executive Summary

Tessellate BIO is a Netherlands-based private biotechnology company founded in 2021, headquartered in Leiden, that is pioneering the discovery of novel synthetic lethal interactions beyond Homologous Recombination Deficiency (HRD). By leveraging advanced proteomics and drug discovery platforms, the company aims to uncover new biology and mechanisms to develop a pipeline of first-in-class precision medicines for cancer patients with significant unmet medical needs. The company's approach targets synthetic lethality, an emerging paradigm that exploits specific genetic vulnerabilities in tumor cells while sparing normal tissue, potentially expanding the therapeutic landscape beyond currently addressed HRD-related cancers. Tessellate BIO's research focuses on identifying and validating new synthetic lethal pairs, which may lead to breakthrough therapies for hard-to-treat malignancies. As a privately held, early-stage company, Tessellate BIO has not disclosed its funding history or valuation, but its innovative strategy and location in the vibrant Leiden biotech cluster position it for potential growth. With no disclosed pipeline or clinical-stage assets, the company is likely in the preclinical or discovery phase, focusing on target identification and validation. The executive summary underscores Tessellate BIO's potential to contribute to the next wave of precision oncology by addressing areas of high unmet need through novel synthetic lethal mechanisms.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement60% success
• Q2 2027Preclinical Proof-of-Concept Data at Major Conference50% success
• Q3 2027Collaboration or Licensing Agreement with Pharma Partner40% success